Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 14, 2025 • 5:31 PM ET

Date/Time Source News Release
01/06/2025 08:30 AM EST GlobeNewswire Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
11/21/2024 08:30 AM EST GlobeNewswire Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
11/12/2024 04:05 PM EST GlobeNewswire Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
11/04/2024 04:30 PM EST GlobeNewswire Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/09/2024 08:00 AM EDT GlobeNewswire Dyadic Expands Global Presence with Participation in Key Industry Events
09/23/2024 09:50 AM EDT GlobeNewswire Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
08/13/2024 04:05 PM EDT GlobeNewswire Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
07/30/2024 04:00 PM EDT GlobeNewswire Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024
06/28/2024 08:30 AM EDT GlobeNewswire Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
05/30/2024 04:30 PM EDT GlobeNewswire Dyadic to Attend Industry Events in June
Page

Additional News

As of January 14, 2025 • 5:31 PM ET

Date/Time Source News Release
Page